TGTX on Nasdaq

TG Therapeutics

Logo: tgtherapeutics.com3

A commercial stage biopharmaceutical company.1

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Opko Health Inc., INSMED Inc or Legend Biotech, or pick any stock.

  • TickerTGTX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York City1
  • Websitetgtherapeutics.com
  • Incorporated inDE4
  • Business address2 Gansevoort Street, 9Th Floor, New York, Ny 100144
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

TG Therapeutics image from its website
Image: tgtherapeutics.com3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

20.0%Operating margin5
72.6%Net margin5
87.3%Revenue growth, 20255
69.0%Return on equity5
0.38×Debt to equity5
-$25.0MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 97% of the revenue TG Therapeutics broke down this way in fiscal 2025.

  1. Product$606.9M597%up 93% from 2024
  2. License$9.4M51%down 39% from 2024
  3. Royalty$5.6M51%up 601% from 2024
  4. Other Revenue$3.6M51%up 97% from 2024
  5. License revenue$152.0K50%up 0% from 2024
Products and services by year
Products and services202320242025
Product$92.0M$313.7M$606.9M
License$141.7M$15.3M$9.4M
Royalty$0$801.0K$5.6M
Other Revenue$1.5M$1.8M$3.6M
License revenue$140.2M$152.0K$152.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue8¢$100.7M
  • Research and development13¢$160.2M
  • Selling, general and admin18¢$232.0M
  • Income tax27¢$339.8M
  • Profit35¢$447.2M

Out of $616.3M in revenue.5

Financial statements

Revenue67895$616.3M in 2025+405352% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $152.0K$152.0K20192020: $152.0K$152.0K2020+0%2021: $6.7M$6.7M2021+4301%2022: $2.8M$2.8M2022−58%2023: $233.7M$233.7M2023+8290%2024: $329.0M$329.0M2024+41%2025: $616.3M$616.3M2025+87%
Operating income67895$123.3M in 2025
-$400.0M-$200.0M0$200.0M2019: -$169.1M-$169.1M20192020: -$273.6M-$273.6M2020+62%2021: -$344.8M-$344.8M2021+26%2022: -$218.3M-$218.3M2022−37%2023: $20.6M$20.6M20232024: $41.9M$41.9M2024+103%2025: $123.3M$123.3M2025+194%
Net income67895$447.2M in 2025
-$400.0M-$200.0M0$200.0M$400.0M$600.0M2019: -$172.9M-$172.9M20192020: -$279.4M-$279.4M2020+62%2021: -$348.1M-$348.1M2021+25%2022: -$223.8M-$223.8M2022−36%2023: $12.7M$12.7M20232024: $23.4M$23.4M2024+85%2025: $447.2M$447.2M2025+1812%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenue$616.3M$329.0M$233.7M
Cost of revenue$100.7M$38.5M$14.1M
Noncash compensation$16.6M$11.2M$13.0M
Other research and development$143.6M$83.1M$63.2M
Total research and development$160.2M$94.3M$76.2M
Noncash compensation$48.1M$31.4M$24.9M
Other selling, general and administrative$184.0M$122.9M$97.8M
Total selling, general and administrative$232.0M$154.3M$122.7M
Total costs and expenses$493.0M$287.1M$213.0M
Operating income$123.3M$41.9M$20.6M
Interest expense$26.7M$24.0M$12.6M
Other income-$10.8M-$7.7M-$5.0M
Total other expense$15.9M$16.3M$7.6M
Net income before taxes$107.4M$25.6M$13.1M
Income tax benefit (expense)$339.8M-$2.2M-$390.0K
Net income$447.2M$23.4M$12.7M
Basic (in dollars per share)$3.10$0.16$0.09
Diluted (in dollars per share)$2.77$0.15$0.09
Basic (in shares)144.3M shares145.3M shares142.0M shares
Diluted (in shares)161.4M shares160.3M shares148.5M shares

Compare TG Therapeutics with another company

Leadership

Who has led TG Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Douglas Abel2006–2008
  2. Michael S. Weiss2013–now

Chair

  1. Michael S. Weiss2013

President

  1. Douglas Abel2006–2008
  2. Michael S. Weiss2017–2023

Chief financial officer

  1. Michael McGuinness2006–2010
  2. Sean A. Power2012–now

Chief operating officer

  1. Michael McGuinness2010
2010201520202025
Board members and other officers (18)

Former names

  • MANHATTAN PHARMACEUTICALS INCMar 10, 2003 to Apr 27, 20124
  • ATLANTIC TECHNOLOGY VENTURES INCAug 14, 2000 to Mar 10, 20034
  • ATLANTIC PHARMACEUTICALS INCNov 7, 1996 to Feb 4, 20004

Timeline

  1. Jan 2, 2013New chief executive Michael S. Weiss becomes CEO13
  2. Jul 10, 2006New chief executive Douglas Abel becomes CEO14

Filings

174 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 35 major events, 58 insider forms, 21 large holders, 39 other. The latest 20:

  1. Sep 14, 20264 EDGAR
  2. Sep 10, 2026144 EDGAR
  3. Aug 7, 20264 EDGAR
  4. Aug 5, 202610-Q EDGAR
  5. Aug 3, 20268-K EDGAR
  6. Jun 15, 20264 EDGAR
  7. Jun 15, 20264 EDGAR
  8. Jun 15, 20264 EDGAR
  9. Jun 15, 20264 EDGAR
  10. Jun 15, 20264 EDGAR
  11. Jun 12, 20268-K EDGAR
  12. Jun 3, 20268-K EDGAR
  13. May 27, 20268-K EDGAR
  14. May 6, 202610-Q EDGAR
  15. May 6, 20268-K EDGAR
  16. Apr 30, 2026DEF 14A EDGAR
  17. Apr 29, 2026SCHEDULE 13G EDGAR
  18. Mar 27, 2026SCHEDULE 13G/A EDGAR
  19. Mar 20, 20268-K EDGAR
  20. Feb 27, 202610-K EDGAR

The 174 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 21 such filings since October 2021, the latest 10:

  1. Apr 29, 2026SCHEDULE 13G
  2. Mar 27, 2026SCHEDULE 13G/A
  3. Nov 10, 2025SCHEDULE 13G
  4. May 13, 2025SCHEDULE 13G
  5. Jan 8, 2025SCHEDULE 13G/A
  6. Nov 14, 2024SC 13G/A
  7. Oct 7, 2024SC 13G/A
  8. Feb 14, 2024SC 13G/A
  9. Feb 13, 2024SC 13G/A
  10. Jan 26, 2024SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.22,050,045$1.2B0.0%−202,885
Vanguard Portfolio Management LLC7,963,266$437.5M0.0%−310,713
State Street Corp7,786,471$427.8M0.0%−863,295
Vanguard Capital Management LLC6,149,403$337.8M0.0%−453,855
Geode Capital Management, LLC3,642,216$200.1M0.0%+142,300
D. E. Shaw & Co., Inc.3,400,808$186.8M0.1%+2,810,761
Soleus Capital Management, L.P.2,927,895$160.9M5.5%−1,101,424
Clearbridge Investments, LLC2,650,192$145.6M0.1%−560,738
Congress Asset Management Co2,600,123$142.9M0.9%+432,042
Two Sigma Investments, LP2,468,971$135.6M0.1%+926,659
Goldman Sachs Group Inc2,314,279$127.1M0.0%+26,591
Pictet Asset Management Holding SA1,785,951$98.1M0.1%+38,578
Jane Street Group, LLC1,752,646$96.3M0.1%−289,023
Nuveen, LLC1,625,876$89.3M0.0%+178,798
Morgan Stanley1,601,714$88.0M0.0%+193,544
Hood River Capital Management LLC1,600,510$87.9M0.6%+31,339
Northern Trust Corp1,537,059$84.4M0.0%+94,480
Charles Schwab Investment Management Inc1,313,103$72.1M0.0%+18,048
Bank Of America Corp /de/1,309,788$72.0M0.0%−151,514
Dimensional Fund Advisors LP1,210,578$66.5M0.0%+125,723
Fmr LLC1,018,814$56.0M0.0%+738,368
Vanguard Fiduciary Trust Co961,750$52.8M0.0%−6,916
Barclays PLC957,848$52.6M0.0%+841,191
Bank of New York Mellon Corp900,482$49.5M0.0%+13,177
Bnp Paribas Financial Markets860,500$47.3M0.0%−96,526

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteTG Therapeutics logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34